cGAS-STING/IL-12 mRNA LNPs: Systemic Tumor Control Strategy

bioRxiv USA

Overview

Researchers have developed an mRNA lipid nanoparticle (LNP) platform that co-delivers an autoactivated cGAS mutant (R241E) and membrane-tethered IL-12 (IL-12TM) to induce systemic antitumor immunity. The combination restores effector function in tumor-infiltrating T cells and suppresses distal tumors across multiple mouse models. This approach integrates innate DNA sensing with cytokine-driven T cell programming to overcome the limitations of local tumor therapies.

In Depth

Key Findings

The co-delivery of cGAS R241E and IL-12TM via mRNA LNPs promotes systemic tumor control and suppresses distal tumors in multiple mouse models. This therapeutic effect is dependent on CD8+ T cells and IFN-γ signaling within the host. Additionally, the combination has been shown to enhance the responsiveness of tumors to PD-L1 blockade.

Technical Details

The platform utilizes mRNA lipid nanoparticles to coordinate innate immune sensing and T cell activation in situ. The two primary components function as follows:

• cGAS R241E: An autoactivated mutant of cyclic GMP-AMP synthase that autonomously generates cyclic GMP-AMP in vivo, thereby activating host STING signaling and initiating antitumor responses.
• IL-12TM: A membrane-tethered version of interleukin-12 that promotes localized cytokine production.

Together, these components reduce the presence of regulatory T cells and restore the effector function of T cells infiltrating the tumor.

Background & Context

Local tumor therapies frequently fail to induce the systemic immunity necessary to control metastatic disease. To address this, the researchers engineered a system that couples innate DNA sensing with IL-12-mediated T cell functional reinforcement, aiming to create a more robust and widespread immune response than traditional localized treatments.

Significance & Outlook

These findings establish a clinically translatable strategy for integrating cGAS-STING activation with cytokine-driven T cell programming. By coordinating the innate and adaptive immune systems, the platform provides a mechanism to drive systemic tumor control and improve the efficacy of existing immunotherapies, such as PD-L1 blockade.

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.

• Your email and selected fields are used only to deliver the newsletter.
• We never share your information with third parties.
• You can unsubscribe anytime via the link in each email.

See our Privacy Policy for details.

Agree & Continue ▶

Takes about a minute · Unsubscribe anytime